• PN: B117696

COMPONENTS

45x Ab-conjugated beads (S4P10 - Human SLPI Ab-bead). PN: B117696A. One vial containing 100 µL of anti-Human SLPI conjugated to AimPlex Bead S4P10.

25x Biotin-detection (SLPI Biotin-dAb). PN: B117696B. One vial containing 100 µL of biotinylated anti-Human SLPI.

Lyophilized Standard Mix-Human Group 8, Panel B, 11-Plex. PN: HG82011. One vial containing lyophilized recombinant Cystatin C, FGF-1, FGF-19, Flt-3L, GDF-15, Granzyme B, NGAL, PAPP-A, SLPI, RAGE, and ST2.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human Human SLPI. Can be multiplexed with other analytes in Human Group 8.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 2 pg/mL

Quantitation range:

LLOQ: < 5 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 8: Negligible

Sample volume: 15 µL/test

Description:

Secretory Leukocyte Protease Inhibitor (SLPI) is an enzyme that is found in large quantities in bronchial, cervical, and nasal mucosa, saliva, and seminal fluids. SLPI inhibits human leukocyte elastase, human cathepsin G, human trypsin, neutrophil elastase, and mast cell chymase. The gene for SLPI is expressed by cells at many mucosal surfaces located in the tissues of the lungs, cervix, seminal vesicles, and parotid ducts. SLPI is also one of the dominantly present proteins in nasal epithelial lining fluid and other nasal secretions. Many diseases, such as emphysema, cystic fibrosis, and idiopathic pulmonary fibrosis, are characterized by increased levels of neutrophil elastase. SLPI is one of the major defenses against the destruction of pulmonary tissues and epithelial tissues by neutrophil elastase. Several diseases are actually the result of SLPI and α1-antitrypsin defenses being overwhelmed by neutrophil elastase. Diseases associated with SLPI include trichomoniasis and urogenital tuberculosis.

References:

1.      Stetler G, Brewer MT, Thompson RC (Oct 1986). "Isolation and sequence of a human gene encoding a potent inhibitor of leukocyte proteases". Nucleic Acids Research 14 (20): 7883–96. doi:10.1093/nar/14.20.7883. PMC 311822. PMID 3640338.

2.      Clauss A, Lilja H, Lundwall A (Nov 2002). "A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein". The Biochemical Journal 368 (Pt 1): 233–42. doi:10.1042/BJ20020869. PMC 1222987. PMID 12206714.

3.      McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM (Jul 1995). "Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro". The Journal of Clinical Investigation 96 (1): 456–64. doi:10.1172/JCI118056. PMC 185219. PMID 7615818.

4.       Nagashunmugam T, Malamud D, Davis C, Abrams WR, Friedman HM (Dec 1998). "Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus". The Journal of Infectious Diseases 178 (6): 1635–41. doi:10.1086/314511. PMID 9815215.